Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Illustrating its confidence in its proprietary products, the Southern California company has announced an ambitious plan to ...

Photo: Alamy President Donald Trump said Tuesday that pharmaceutical companies could soon face new tariffs, with initial ...

Two Republican senators and a broad coalition of funders made a big difference for private foundations during negotiations over President Donald Trump’s tax and spending legislation ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

Half of those surveyed plan to raise deductibles and maximum out-of-pocket costs for workers. Read more at straitstimes.com. Read more at straitstimes.com.

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite outperforming the medical sector over the past month. Analysts eagerly await its ...

In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

Trump pharma and chip tariffs may start this month, sparking price hikes, inflation, and global trade ripples.

A Nigerian-born health data scientist, David Ajayi, is making waves in the United States through nationally recognized work ...